Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

Meningitis Clinical Trial

Official title:

Antibody Responses to a Reduced Dose of Menomune® in Children Who Previously Received an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, TetraMenD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00772070
• Other study ID #: MTA17
• Status: Completed
• Phase: Phase 2
• First received: October 13, 2008
• Last updated: January 21, 2014
• Start date: March 2003
• Est. completion date: May 2004

Study information

• Verified date: January 2014
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study was designed to simulate meningococcal challenge by vaccination with a fractional combined dose of unconjugated meningococcal polysaccharides A, C, Y, and W-135, Menomune® in children who were vaccinated with one dose of TetraMenD at least 18 months earlier.

Primary Objective:

To evaluate and compare the antibody responses to a reduced dose of Menomune® in participants who had previously received a tetravalent meningococcal diphtheria toxoid conjugate vaccine to those responses in participants who received the same reduced dose of Menomune® but had not previously received any meningococcal vaccine.

Description:

This was a two stage, controlled, open-label trial. Stage I of the trial simulated meningococcal challenge Stage II of the trial evaluated the meningococcal vaccine naïve participants from Stage I, who had also received a reduced dose of Menomune® vaccine in Stage I and were administered a full dose of Menactra® vaccine 6 months later.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 173
• Est. completion date: May 2004
• Est. primary completion date: August 2003
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 3 Years to 5 Years

Eligibility

Inclusion Criteria :

• Stage I

• Participant is healthy, as determined by medical history and physical examination.

• Participant is at least 3 years of age but not yet 6 years of age at the enrolment.

• For the TetraMenD group: received one dose of TetraMenD as a participant in trial 603-02 no less than 18 months prior to enrolment

• For the Control group: no previous history of any meningococcal vaccination

• Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form.

• Stage II

• Participant is healthy, as determined by medical history and physical examination.

• Participant is at least 3 years of age but not yet 6 years of age at the time of enrollment in Stage 1.

• Enrolled in the Control group only and received one dose of the reduced dose Menomune at Stage 1.

• Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form.

Exclusion Criteria :

• Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc.)

• Known or suspected impairment of immunologic function

• Acute medical illness with or without fever within the last 72 hours or an axillary temperature (= 99.5ºF [= 37.5ºC]) at the time of inclusion

• For Stage I, history of documented invasive meningococcal disease or previous meningococcal vaccination with exception of those participants recruited from Trial 603-02.

• For Stage II, history of documented invasive meningococcal disease or participant did not receive Reduced-dose Menomune® six months prior.

• Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.

• Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy within the 72 hours prior to having any blood sample drawn

• Received any vaccine in the 28-day period prior to study vaccination, or scheduled to receive any vaccination during the 28-day period after study vaccination in Stage 1 of the trial.

• Suspected or known hypersensitivity to any of the vaccine components

• Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures

• Enrolled in another clinical trial

• Any condition, which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Meningitis
• Meningococcemia
• Neisseria Meningitidis

Intervention

Biological:
• A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
0.05 mL, Subcutaneous
• A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
0.05 mL, Subcutaneous

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

United States, 

References & Publications (1)

Pichichero M, Papa T, Blatter M, Mitchell D, Kratz R, Sneed J, Bassily E, Casey J, Gilmet G. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. Pediatr Infect — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Percentage of Participants With at Least a 4-fold Rise in Serum Bactericidal Activity to Each Vaccine Meningococcal Serogroups.		Baseline to Day 8 and Day 28 post-vaccination	No
Other	Percentage of Participants Reporting Solicited Local and Systemic Reactions Within Days 0 to 7 Post-vaccination.		Day 0 to 7 post-vaccination	Yes
Primary	Geometric Mean Titers (GMT) of Serum Bactericidal Activity for Each Vaccine Serogroups Before and Post-vaccination.		Day 0 and Days 8 and 28 post-vaccination	No

External Links

•   Link
•   Link